secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-11-16T23:59:59+00:00
Accession:  0001628280-23-039211
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Avalo Therapeutics extension to Dec 29 to regain $1 bid price
---------------------------------------------------------------------------

- Received Nasdaq notice on Nov 14, 2023 of Panel granting exception from MVLS and bid price rules until Dec 29, 2023.
- Condition 1 already met: Company filed Form 10-Q on Nov 9 showing stockholders' equity of $14.7M, satisfying Nasdaq equity requirement.
- Condition 2: Must maintain closing bid price of $1.00 for ten consecutive sessions by Dec 29 to avoid delisting.
- Previously, on Sep 13, Nasdaq notified Company of low-priced stock rule due to bid price <=$0.10 for ten consecutive days.
- No assurance of regaining compliance; risk of delisting remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/0001628280-23-039211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/avtx-20231114.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-039211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer